Simpson Thacher is representing Warburg Pincus in connection with the launch of Vertice Pharma, LLC with an equity investment of up to $300 million. Warburg Pincus has partnered with pharmaceutical industry veterans, Don DeGolyer and Andrew Saik to launch the new company. Vertice Pharma also announced a definitive merger agreement to acquire VistaPharm. The terms of the transaction were not disclosed.
Vertice Pharma is a specialty pharmaceuticals company that develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies.
VistaPharm, founded in 1998, is a Florida-based healthcare company that specializes in delivering generic pharmaceutical and OTC products for the hospital market, retail pharmacy and specialized clinical setting.
The Simpson Thacher team included Robert Langdon, Austen Heim and Colin Lloyd (M&A – U.S.); Mike Wolfson, Neil Evans and Chris Vallance (M&A – U.K.); Jason Vollbracht and Judy Yan (Tax); David Rubinsky, Jeannine McSweeney and Eric Wolf (Executive Compensation and Employee Benefits); Jennifer Hobbs, Brian Gluck and Homin Lee (Debt); Timothy Mulvihill (Environmental); Peter Thomas and Michael Naughton (Antitrust); and Genevieve Dorment (Intellectual Property).